Distinct Lipidomic Profiles between People Living with HIV Treated with E/C/F/TAF or B/F/TAF: An Ope...
Distinct Lipidomic Profiles between People Living with HIV Treated with E/C/F/TAF or B/F/TAF: An Open-Label Prospective Cohort Study
About this item
Full title
Author / Creator
Wan, Zhikai , Su, Junwei , Zhu, Xueling , Liu, Xiang , Guo, Yongzheng , Xiang, Dairong , Zhou, Xiaotang , Peng, Xiaorong , Tao, Ran , Cao, Qing , Lang, Guanjing , Huang, Ying and Zhu, Biao
Publisher
Cheshire: Springer Healthcare
Journal title
Language
English
Formats
Publication information
Publisher
Cheshire: Springer Healthcare
Subjects
More information
Scope and Contents
Contents
Introduction
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) has been increasingly replaced by bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in the treatment of human immunodeficiency virus (HIV) owing to its more favorable pharmacokinetics and fewer drug–drug interactions. However, the effect of this switch o...
Alternative Titles
Full title
Distinct Lipidomic Profiles between People Living with HIV Treated with E/C/F/TAF or B/F/TAF: An Open-Label Prospective Cohort Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_9c8ef275230f4b3cab4694c9139f330d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9c8ef275230f4b3cab4694c9139f330d
Other Identifiers
ISSN
2193-8229
E-ISSN
2193-6382
DOI
10.1007/s40121-024-00943-0
